The PI3K inhibitor alpelisib (Piqray, Novartis Europharm Limited, Ireland) was the first FDA-approved breast cancer drug for hormone-receptor-positive and HER2-negative patients. This evidence concerns the gene NR4A1 and breast carcinoma.